Cellular Repair & Recovery
ARA-290
Cibinetide
ARA-290 (Cibinetide)
Research context
ARA-290 corresponds to a sequence within the helix B domain of erythropoietin, designed to engage the innate repair receptor without the erythropoietic activity of the full protein. Research examines receptor complex binding and inflammatory endpoints in tissue models.
Common assays: Innate repair receptor binding · Cytokine quantification · Erythropoietic activity comparison
Specification
| Designation | Cibinetide |
|---|---|
| Full name | ARA-290 (Cibinetide) |
| Sequence | Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser |
| CAS number | 1208243-50-8 |
| Molecular formula | C48H82N16O18 |
| Molecular weight | 1179.27 g/mol |
| Formats | 10 mL Vial |
| Solubility | Sterile water, bacteriostatic water |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C. |
| Regulatory status | Not an approved drug. Listed in FDA 503A Category 3 (nominated without adequate supporting information) as of October 2026. 2026 status by compound → |
| Current lot | ARA10VAS0426 → |
ARA-290 COA: certificates of analysis by lot
One lot of ARA-290 has a published certificate of analysis from AxisPharm, LLC, an independent laboratory. Each certificate reports the laboratory's results for that lot.
| Lot | Format | Purity (HPLC-UV) | Reported |
|---|---|---|---|
| ARA10VAS0426 | 10 mg Vial | >99.3% | 2026-04-30 |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Brines M, Patel NS, Villa P, et al.Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietinProceedings of the National Academy of Sciences · 2008 Find on PubMed ↗
Common questions
How does ARA-290 differ from erythropoietin?
It corresponds to only the helix B region and was designed specifically to lack the erythropoietic activity of the full protein while retaining engagement with the innate repair receptor complex.
Where can I see the ARA-290 certificate of analysis?
Every published ARA-290 lot has its own certificate page on this site, listed under "ARA-290 COA" above. There is one published lot; the most recent, lot ARA10VAS0426, was reported on 2026-04-30 at >99.3% purity by HPLC-UV. The certificates are issued by AxisPharm, LLC, an independent laboratory.
Components, blends and pathway
Related compounds
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a gastric juice sequence, studied in migration and angiogenesis models.
TB-500
Thymosin beta-4 fragment
A synthetic fragment corresponding to the actin-binding domain of thymosin beta-4.
Wolverine
BPC-157 / TB-500
A prepared blend of the two most extensively studied compounds in the repair signalling literature.
KLOW
BPC-157 / TB-500 / GHK-Cu / KPV
A prepared four-component blend combining repair-signalling and cytokine-pathway compounds.